Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Mark G LebwohlLinda Stein GoldBruce StroberKim A PappApril W ArmstrongJerry BagelLeon KircikBenjamin EhstH Chih-Ho HongJennifer SoungJeff FromowitzScott GuenthnerStephen C PiscitelliDavid S RubensteinPhilip M BrownAnna M TallmanRobert BissonnettePublished in: The New England journal of medicine (2021)
Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was associated with local adverse events and headache. Larger and longer trials are needed to evaluate the efficacy and safety of tapinarof cream as compared with existing treatments for psoriasis. (Funded by Dermavant Sciences; PSOARING 1 and 2 ClinicalTrials.gov numbers, NCT03956355 and NCT03983980, respectively.).